India's new budget cuts selected drug duties and extends R&D tax breaks
This article was originally published in Scrip
India's federal budget for 2012-13 gave a little to parts of the pharmaceutical industry, but took away a lot. On the plus side, there are import duty cuts for certain vaccines, anticancers, and HIV/AIDS drugs, while extending tax breaks on specific in-house R&D. But then it raised excise duty on all non-petroleum products from 10% to 12%.